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MaOBJECTIVES The aim of this study was to determine whether transcatheter aortic valve replacement (TAVR) with the
mechanically expanded Lotus valve (Boston Scientiﬁc, Natick Massachusetts) offers potential beneﬁts over treatment
with the self-expanding CoreValve (Medtronic, Minneapolis, Minnesota).
BACKGROUND New-generation transcatheter aortic valve systems are emerging in clinical trials and practice with
design features aimed at improving safety and efﬁcacy. To date, these devices have not been compared systematically
with current-generation devices.
METHODS A total of 100 patients (83.4  4.8 years of age, 44% male, Society of Thoracic Surgeons Predicted Risk
of Mortality score of 5.5  2.4) were assessed. Fifty consecutive patients undergoing a Lotus transcatheter aortic
valve replacement were enrolled and compared with 50 matched patients treated with a CoreValve. An independent core
laboratory reviewed all echocardiographic data, and an independent clinical events committee adjudicated all events.
RESULTS Valve Academic Research Consortium 2–deﬁned device success was 84% and 64% in the Lotus and CoreValve
cohorts, respectively (p ¼ 0.02). This difference was driven by lower rates of moderate or greater aortic regurgitation
(4% vs. 16.7%, respectively; p ¼ 0.04) and higher rates of successfully implanting a single device in the correct anatomic
position (100% vs. 86%, respectively; p ¼ 0.06). Cardiovascular mortality rate (0% vs. 4%, respectively; p ¼ 0.32),
major stroke rate (4% vs. 2%, respectively; p ¼ 0.56), and permanent pacemaker insertion rate (28% vs. 18%,
respectively; p ¼ 0.23) were not different at 30 days in the Lotus and CoreValve cohorts.
CONCLUSIONS In this matched comparison of high surgical risk patients undergoing transcatheter aortic valve
replacement, the use of the Lotus device was associated with higher rates of Valve Academic Research Consortium
2–deﬁned device success compared with the CoreValve. This was driven by higher rates of correct anatomic positioning
and lower incidences of moderate paraprosthetic regurgitation. The clinical signiﬁcance of these differences needs to be
tested in a large randomized, controlled trial. (J Am Coll Cardiol Intv 2015;8:962–71) © 2015 by the American College of
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AB BR E V I A T I O N S
AND ACRONYM S
EOA = effective oriﬁce area
MDCT = multidetector
computed tomography
PAR = paraprosthetic aortic
regurgitation
TAVR = transcatheter aortic
valve replacement
TTE = transthoracic
echocardiography
VARC2 = Valve Academic
Research Consortium 2
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963T ranscatheter aortic valve replacement (TAVR)has proved to be a safe and effective treatmentfor severe aortic stenosis in appropriately
selected high and extremely high surgical risk pa-
tients (1,2). Since its inception in 2002 (3), TAVR
has gained wide acceptance and clinical approval in
many countries on the basis of a rapidly growing
body of evidence. As a result, adoption of the technol-
ogy and implant rates have grown nearly exponen-
tially (4,5).
Most global TAVR experience has been obtained
with either the Edwards SAPIEN or SAPIEN XT
(Edwards Lifesciences, Irvine, California) or the Med-
tronic CoreValve device, (Minneapolis, Minnesota);
however, a growing number of next-generation pros-
theses are now entering clinical trials and routine
practice (6–9). Most of these devices incorporate novel
features designed to reduce the modest yet impor-
tant complications identiﬁed with current-generation
devices. Data supporting enhanced safety and efﬁ-
cacy of new-generation devices, however, are modest
and derived from single-arm studies.
The CoreValve Revalving System (Medtronic) is a
self-expanding device fashioned from nitinol wire.
The distinctive frame has a ﬂared inﬂow portion to
anchor in the native annulus, a constrained midseg-
ment to avoid coronary obstruction, and a ﬂared
outﬂow portion to improve coaxial alignment to the
aortic ﬂow plane. In a U.S. pivotal trial, the CoreValve
was found to have a signiﬁcantly higher survival rate
at 1 year than surgical valve replacement in a high-
risk cohort (10). These results mirror favorable
safety and efﬁcacy data from large single-center
(11,12), national (13–15), and multinational (16)
registries.
The Lotus device (Boston Scientiﬁc, Natick, Mas-
sachusetts) is a new TAVR device that uses a unique
mechanical expansion mechanism. It is made of a
single braided nitinol wire and 3 bovine pericardial
leaﬂets. The outer surface of the lower half of the
frame is covered with an adaptive seal, essentially
a polymer membrane that concertinas as the device
is expanded and, in doing so, occupies any small
residual interstices, sealing the frame against the
native aortoventricular interface (8,17). This has been
reported to reduce the rate of paraprosthetic aortic
regurgitation (PAR). The device is fully repositionable
and resheathable, even in the completely expanded
position, allowing for ﬁne control and the potential
for removal should the device position or size be
deemed suboptimal. The Lotus device was studied
in the REPRISE I (Repositionable Percutaneous Re-
placement of Stenotic Aortic Valve Through Implan-
tation of Lotus Valve System) (18), the REPRISE II(Repositionable Percutaneous Replacement
of Stenotic Aortic Valve Through Implanta-
tion of Lotus Valve System—Evaluation of
Safety and Performance) (19), and REPRISE II
Extension single-arm trials.
Although there has been an adoption of
new devices such as the Lotus at some cen-
ters, to date, there have been no systematic
head-to-head comparisons, with indepen-
dent core laboratory assessments, of devices
to accurately determine their relative safety
and efﬁcacy.METHODS
STUDY POPULATION. A total of 100 patients (mean
age, 83.4  4.8 years, 44% male) with symptomatic
severe aortic stenosis were included in this study.
Fifty consecutive and prospectively enrolled patients
receiving a Lotus transcatheter device were compared
with 50 matched patients who had undergone TAVR
with the CoreValve device during the same period.
All patients were treated at a single Australian
center. All patients were deemed to be at high or
extremely high surgical risk because of an increased
Society of Thoracic Surgeons Predicted Risk of
Mortality score (higher than 8) and/or the collective
opinion of the institution’s Heart Team after a
comprehensive history, examination, and frailty
assessment (dominant hand-grip strength, 5-m gait
speed, and serum albumin). Patients were eligible
for inclusion if they had severe aortic stenosis based
on echocardiographic criteria (mean transaortic
gradient $40 mm Hg or aortic velocity $4 m/s and an
aortic valve area #1 cm2 or indexed aortic valve
area #0.7 cm2/m2) and reported symptoms attribut-
able to severe aortic stenosis (Table 1).
All patients were assessed in a systematic and
standardized manner beginning with their atten-
dance and clinical evaluation at our Structural Heart
Disease Clinic. All patients underwent multidetector
computed tomography (MDCT), transthoracic echo-
cardiography (TTE), invasive angiography, and right
heart catheterization before inclusion. Only patients
who had MDCT annular sizing that allowed for
treatment with either device (according to the
respective instructions for use) and were treated
via the femoral access route were considered suitable
for the study. Patients were matched on age,
sex, Society of Thoracic Surgeons score, and frailty
indexes.
PRE-PROCEDURAL MDCT ASSESSMENT. All patients
underwent prospectively electrocardiography-gated,
TABLE 1 Inclusion and Exclusion Criteria
Inclusion criteria
1. Severe aortic stenosis
Mean aortic gradient $40 mm Hg or aortic velocity $4 m/s
AVA #1 cm2 or indexed AVA #0.7 cm2/m2
2. Symptoms consistent with aortic stenosis
NYHA functional class II–IV dyspnea
Exertional angina
Exertional syncope or pre-syncope
3. High or extreme surgical risk
STS PROM $8 or heart team agreement that patient
is at high surgical risk
4. Suitable aortic root anatomy for placement of either a Lotus*
or CoreValve† prosthesis
MDCT-derived annular dimension $19 mm and #27 mm
5. Suitable peripheral vasculature for passage of an
18-/20-F sheath
Exclusion criteria
1. Inability to consent
*Boston Scientiﬁc, Natick, Massachusetts. †Medtronic, Minneapolis, Minnesota.
AVA ¼ aortic valve area; NYHA ¼ New York Heart Association; STS PROM ¼
Society of Thoracic Surgeons Predicted Risk of Mortality; MDCT ¼ multidetector
computed tomography.
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964320-MDCT imaging of the aortic root at baseline. All
scans were performed on a Toshiba Aquilion One
320-detector row scanner (Toshiba Medical Systems,
Otawara, Japan). No heart rate control was used.
Collimation was individualized to achieve a z-axis
that encompassed the entire aortic root. Slice
thickness was 0.5 mm. Gantry rotation speed was
275 ms per rotation, tube voltage was 100 to 120
kV, and the tube current was individualized to
body habitus. Intravenous contrast (Omnipaque 350,
GE Healthcare, Little Chalfont, Buckinghamshire,
United Kingdom) was administered via an 18-gauge
antecubital vein as a 70-ml bolus followed by a
50-ml saline solution bolus at a rate of 6 ml/s.
Systolic phase images (20) were acquired after
manual triggering by monitoring for contrast den-
sity in the descending aorta to ensure adequate
contrast opaciﬁcation.
All MDCT scans were analyzed by an experienced
computed tomography cardiologist using the 3Mensio
valve analysis program (3Mensio Medical Imaging,
Bilthoven, the Netherlands). The annular plane was
identiﬁed as the short axis through the nadir of
each coronary cusp, and diameters, perimeter, and
area were measured. The eccentricity was calculated
using the eccentricity index (eccentricity index ¼ 1 
minimal diameter/maximal diameter). Further mea-
surements were taken in the left ventricular outﬂow
tract 4 mm below the annular plane, sinus of Val-
salva, ascending aorta, and height of the coronary
arteries.Sizing of TAVR devices was guided by the
3-dimensional MDCT measurements and strictly con-
formed with the respective manufacturer’s in-
structions for use. The degree of oversizing for each
device was calculated based on annular plane perim-
eter (perimeter oversizing ¼ (device perimeter 
annular perimeter)/annular perimeter  100) and
annular plane area (area oversizing ¼ (device area 
annular area)/annular area  100).
PRE-PROCEDURAL TTE ASSESSMENT. TTE was per-
formed using an iE33 machine (Philips, Best, the
Netherlands) before enrollment. All scans were
assessed by an experienced echocardiologist with
severity of aortic stenosis graded based on European
Association of Echocardiography and American Soci-
ety of Echocardiography joint guidelines (21). An
independent echocardiography core laboratory sub-
sequently reviewed these studies with these results
used for study analysis.
PRE-PROCEDURAL INVASIVE ANGIOGRAPHIC
ASSESSMENT. All patients underwent invasive coro-
nary and peripheral angiography to conﬁrm access
site suitability and to identify signiﬁcant coronary
artery disease warranting treatment before TAVR.
Treatment of concomitant coronary artery disease
was at the discretion of the implanting cardiologist.
Right heart catheterization was performed to ex-
clude signiﬁcant primary pulmonary hypertension
and corroborate ultrasound-based hemodynamic
measurements.
TREATMENT. All TAVR procedures were performed
in the cardiac catheterization laboratory with patients
under general anesthesia or conscious sedation.
Three experienced TAVR cardiologists performed all
procedures with 2 operators present at each proce-
dure. The femoral artery was used for device access in
all cases with an 18-F Cook sheath (Cook Medical,
Bloomington, Indiana) used for all CoreValve pro-
cedures, whereas an 18-F Lotus Introducer (Boston
Scientiﬁc) was used for 23-mm Lotus cases and 20-F
Lotus Introducer for those receiving a 27-mm Lotus
valve. The femoral access site was managed uni-
formly in all patients. The designated femoral access
was routinely “pre-closed” with either a single Pros-
tar or 2 Proglide devices (Abbott Vascular, Abbott
Park, Illinois), and ﬁnal access site closure was
performed using a crossover balloon occlusion tech-
nique (22).
Balloon valvuloplasty was performed in all pa-
tients under rapid ventricular pacing to enable
maximal balloon stability. Valvuloplasty balloons
were sized so as to not exceed the minimal diameter
of the left ventricular outﬂow tract.
TABLE 2 Baseline Characteristics
Lotus*
(n ¼ 50)
CoreValve†
(n ¼ 50) p Value
Age, yrs 84.0  5.2 82.7  4.5 0.19
Male 18 (36) 26 (52) 0.11
Height, cm 161.4  10.0 163.8  8.9 0.20
Weight, kg 72.9  17.2 73.9  14.6 0.75
Body mass index, kg/m2 28.1  6.6 27.5  4.8 0.62
STS PROM, % 5.80  2.40 5.21  2.47 0.23
STS M&M 26.21  7.44 23.97  6.08 0.10
Charlson Comorbidity Index 2.7  2.0 2.6  1.4 0.65
Hand grip strength 16.6  7.0 16.0  6.3 0.73
5-m gait speed 9.9  3.0 9.5  2.9 0.55
Serum albumin 33.9  5.6 32.1  5.8 0.12
NYHA functional class
II 7 (14) 13 (26)
III 36 (72) 36 (72)
IV 7 (14) 1 (2) 0.05
Creatinine, mmol/l 97.6  57.3 103.2  28.4 0.54
Type 2 diabetes mellitus 10 (20) 12 (24) 0.63
Existing coronary artery disease 29 (58) 33 (66) 0.41
Previous coronary bypass surgery 7 (14) 15 (30) 0.05
Peripheral vascular disease 3 (6) 6 (12) 0.30
Chronic pulmonary disease 14 (28) 16 (32) 0.66
Atrial ﬁbrillation 5 (10) 14 (28) 0.02
Existing permanent pacemaker 5 (10) 7 (14) 0.54
Values are mean  SD or n (%). *Boston Scientiﬁc, Natick, Massachusetts. †Medtronic,
Minneapolis, Minnesota.
STS M&M ¼ Society of Thoracic Surgeons Morbidity and Mortality; other abbreviations
as in Table 1.
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965Deployment of the respective devices was per-
formed in strict accordance with manufacturer’s
guidelines and current best practices (8,16,17).
Aortic regurgitation was assessed by aortography
after ﬁnal deployment using 20 ml of iodinated
contrast delivered at 20 ml/s and 800 psi by auto-
mated injector through a 5-F pigtail catheter posi-
tioned above the prosthesis leaﬂets. Moderate or
greater aortic regurgitation, identiﬁed at the time of
deployment by either imaging modality and/or
haemodynamic assessment, was treated by post-
dilation in the CoreValve cohort and repositioning
in the Lotus cohort. Aortography was repeated after
ﬁnal device manipulation to reassess ﬁnal degree
of PAR and to exclude the need for further
manipulation.
INDEPENDENT CORE LABORATORY ECHOCARDIO-
GRAPHIC ASSESSMENT. All patients had a TTE study
performed on day 7 to 10 or on the day of discharge,
if this occurred earlier, and again at 30 days after
TAVR. The independent core laboratory assessed
prosthesis function, degree, and location of aortic
regurgitation, severity of mitral regurgitation, left
ventricular function, and pulmonary artery pressure.
Prosthetic regurgitation was assessed in accordance
with Valve Academic Research Consortium 2 (VARC2)
(23) recommendations.
CLINICAL REVIEW. A study investigator reviewed
patients at the time of each echocardiogram, and a
detailed history was taken and an examination per-
formed. New York Heart Association functional class
was determined on the basis of the patient’s self-
reporting of symptoms.
ENDPOINTS. The primary endpoint of the trial was
VARC2-deﬁned device success (23). This is a com-
posite endpoint that includes the absence of proce-
dural mortality, correct positioning of a single
prosthesis in the correct anatomic position, and
intended prosthesis function (no prosthesis-patient
mismatch, mean aortic valve gradient <20 mm Hg,
peak velocity <3 m/s, and no moderate or greater
aortic regurgitation on TTE at time of discharge).
Prosthesis function was determined by core labora-
tory assessment of the discharge echocardiogram.
Secondary endpoints were all-cause and cardio-
vascular mortality at 30 days, minor and major
bleeding, minor and major vascular injury, new
pacemaker insertion, and disabling and nondisabling
stroke.
STATISTICAL ANALYSIS. Categorical variables were
expressed as frequencies and percentages, whereas
continuous variables were expressed as means andSDs. Categorical variables were compared using a chi-
square test, whereas nonparametric continuous vari-
ables were compared using the Mann-Whitney or
independent-sample t test. A 2-sided p value <0.05
was considered statistically signiﬁcant. Statistical
analysis was performed using IBM SPSS Statistics
version 22.0 (IBM Corporation, Armonk, New York).
RESULTS
BASELINE CHARACTERISTICS. The baseline de-
mographic and clinical characteristics are described
in Table 2. In brief, there were no clinically signiﬁcant
differences between the 2 study populations other
than a higher proportion of patients with NYHA
functional class IV symptoms in the Lotus cohort and
more patients with pre-existing atrial ﬁbrillation in
the CoreValve cohort. Baseline Society of Thoracic
Surgeon scores, Charlson Comorbidity Index, and
frailty index were similar.
Baseline echocardiographic parameters of aortic
stenosis severity were not signiﬁcantly different
between the Lotus and CoreValve cohorts, with
average mean gradients of 44.9  12.9 mm Hg and
47.3  12.5 mm Hg, respectively (p ¼ 0.34). There
TABLE 3
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966were no differences in the proportion of patients
with mild, moderate, or severe aortic regurgitation
at baseline. MDCT annular dimensions, whether
diameter, perimeter, or perimeter-derived metrics,
were well matched. The basal plane was slightly
more eccentric among the CoreValve cohort (eccen-
tricity index: 0.20  0.06 vs. 0.23  0.06, p ¼ 0.02).
Left ventricular outﬂow tract, sinus dimensions, and
height of the coronary arteries above the basal plane
were similar. Full baseline anatomic dimensions are
shown in Table 3.
PROCEDURAL DETAILS. Twenty-six patients (52%)
in the Lotus cohort were treated with the smallerPre-procedural Echocardiographic and Computed Tomographic
ssessment
Lotus*
(n ¼ 50)
CoreValve†
(n ¼ 50) p Value
cic echocardiography
radient 44.9  12.9 47.3  12.5 0.34
0.70  0.17 0.67  0.16 0.35
exed 0.41  0.10 0.39  0.07 0.41
onless index 0.23  0.05 0.22  0.05 0.39
ary artery pressure 41.3  11.4 39.1  9.8 0.34
tricular ejection fraction 56.4  9.1 54.9  9.2 0.51
gurgitation
/trivial 29 (58) 25 (50)
14 (28) 25 (50)
rate 7 (14) 0 0.01
d regurgitation
/trivial 22 (44) 30 (60)
23 (46) 17 (34)
rate 5 (10) 2 (4)
rate/severe 0 0
e 0 1 (2) 0.22
egurgitation
/trivial 21 (42) 20 (40)
23 (46) 28 (56)
rate 6 (12) 2 (4) 0.28
tor computed tomography
ane
al diameter 21.2  1.9 21.0  2.0 0.68
al diameter 26.5  2.1 27.3  2.2 0.09
tricity index 0.20  0.06 0.23  0.06 0.02
eter 75.6  5.5 76.5  5.8 0.42
435.7  63.4 447.1  68.9 0.40
tricular outﬂow tract
al diameter 19.2  2.6 19.5  2.4 0.59
al diameter 27.4  2.7 27.7  2.8 0.54
tricity index 0.30  0.09 0.30  0.07 0.99
eter 74.6  6.8 75.8  6.8 0.36
405.8  80.5 424.9  77.3 0.23
Valsalva
776.8  122.2 831.3  136.2 0.04
ean  SD or n (%). *Boston Scientiﬁc, Natick, Massachusetts. †Medtronic,
, Minnesota.
rtic valve area.Lotus device (23 mm), whereas 22 patients (44%) in
the CoreValve group received the smaller CoreValve
prosthesis (26 mm) (p < 0.001). There was greater
perimeter oversizing (3.6  5.7% vs. 14.0  6.2%, p <
0.001) and area oversizing (13.0  12.3% vs. 36.6 
15.4%, p < 0.001) in the CoreValve cohort. All patients
left the catheterization laboratory with a functioning
TAVR prosthesis. There were no differences in pro-
cedure duration (Table 4).
The primary outcome measure of VARC2-deﬁned
device success was achieved in 84% of the Lotus
cohort and 64% of the CoreValve cohort (p ¼ 0.02).
The components of this outcome measure were
the absence of procedural mortality (100% vs. 96%;
p ¼ 0.15), correct positioning of a single prosthesis
(100% vs. 86%; p ¼ 0.06), mean gradient across the
prosthesis <20 mm Hg (96% vs. 100%; p ¼ 0.16),
absence of prosthesis-patient mismatch (92% vs.
86%; p ¼ 0.68), and no more than mild aortic regur-
gitation (96% vs. 83.3%; p ¼ 0.04) in the Lotus and
CoreValve cohorts, respectively (Figure 1).
All-cause death was 0% in the Lotus cohort and 4%
in the CoreValve cohort at 7 days. At 7 days, 1 death
in the CoreValve cohort was due to ischemic colitis
after a partially deployed prosthesis was retrieved
through the aorta, whereas the other death was due
to progressive congestive cardiac failure in the setting
of severe PAR that was refractory to post-dilation.
There was 1 additional death in the Lotus cohort at
30 days due to a hemorrhagic stroke, and 1 additional
death in the CoreValve cohort due to pneumonia and
respiratory failure.
There was no signiﬁcant difference in the rates of
acute kidney injury, minor or major vascular injury,
disabling or nondisabling stroke, or periprocedural
myocardial infarction. The rate of new pacemaker
insertion was greater in the Lotus cohort (28% vs.
18%), although not statistically different (p ¼ 0.23)
(Figure 2).
CORE LABORATORY DISCHARGE ASSESSMENT. The
mean transprosthetic gradients were 12.4 4.2 mmHg
and 8.5  2.9 mm Hg (p < 0.001) for the Lotus and
CoreValve cohorts, respectively. The mean effective
oriﬁce areas (EOAs) were similar in both cohorts
(1.6  0.3 cm2 vs. 1.7  0.4 cm2, p ¼ 0.07). There were
no differences in the severity of mitral regurgita-
tion, pulmonary artery pressure, or left ventricular
function (Table 5).
Core laboratory–adjudicated PAR was mild in
14% and 56.2% (p < 0.001) and moderate in 4%
and 16.7% (p ¼ 0.04) of the Lotus and CoreValve
cohorts, respectively. Although 1 patient in the
CoreValve cohort died of complications of severe
FIGURE 1 Device Success and Composites
Primary outcome measure of Valve Academic Research Consortium 2–deﬁned device
success and its composites. AR ¼ aortic regurgitation.
TABLE 4 Procedural Characteristics
Lotus* (n ¼ 50) CoreValve† (n ¼ 50) p Value
Device size <0.001
Small (23-mm Lotus, 26-mm CoreValve) 26 (52) 22 (44)
Large (27-mm Lotus, 29-mm CoreValve) 24 (48) 28 (56)
Sheath size, Fr <0.001
18 26 (52) 50 (100)
20 24 (48) 0 (0)
Prosthesis oversizing
Perimeter 3.6  5.7 13.0  12.3 <0.001
Area 14.0  6.2 36.6  15.4 <0.001
No. of devices used 1.12  0.32 1.14  0.40 0.79
Post-dilation 0 (0) 13 (26) <0.001
Procedure duration, min 118.0  39.2 114.2  35.8 0.62
*Boston Scientiﬁc, Natick, Massachusetts. †Medtronic, Minneapolis, Minnesota.
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967PAR before the discharge TTE time point, there
were no further cases of severe PAR in those
patients alive at 7 days.
CORE LABORATORY 30-DAY ASSESSMENT. There
was no deterioration in valve function as assessed by
TTE at 30 days by mean transprosthetic gradient or
EOA. The mean transprosthetic gradient remained
signiﬁcantly higher in the Lotus cohort than the
CoreValve cohort (12.6  6.5 mm Hg and 8.2  2.6
mm Hg, respectively; p < 0.001), with no difference in
the prosthesis EOA (1.7  0.4 cm2 vs. 1.8  0.4 cm2,
respectively; p ¼ 0.17).
Moderate PAR occurred in 0% and 10.6% (p ¼ 0.02)
of patients in the Lotus and CoreValve cohorts,
respectively, with no cases of severe PAR at 30 days.
The percentage of patients with mild AR was similar
to that at discharge: 14.3% and 66% (p < 0.001),
respectively (Table 5).
FUNCTIONAL ASSESSMENT. There was a signiﬁcant
improvement in New York Heart Association score in
both cohorts with 79.2% of patients in the Lotus
group and 82.9% in the CoreValve group, improving
by 1 class or more (Figure 3).
DISCUSSION
There is a substantial body of evidence supporting
the efﬁcacy and safety of TAVR as an alternate
treatment to surgical valve replacement in high-risk
patients (1,10) and its superiority to medical therapy
in patients denied surgery due to extreme risk (2).
Despite improvements in patient selection, the utility
of 3-dimensional computed tomography image-based
sizing algorithms and deployment techniques, a
number of limitations remain with the current tech-
nologies. These include vascular access complica-
tions (24,25), need for permanent pacemaker after
implantation (26,27), PAR (28), and stroke (29,30).
Although second-generation devices, designed to
address some of these limitations, are emerging in
both clinical trials and clinical practice, the evidence
supporting their safety and efﬁcacy is limited. This
study was designed to systematically compare a
widely accepted and well-studied current-generation
device, the CoreValve, with an emerging new-
generation device, the Lotus valve.
In this nonrandomized, single-center study, we
observed that both the Lotus and CoreValve devices
were associated with high rates of procedural suc-
cess, although the VARC2-deﬁned primary compos-
ite outcome of device success was higher in the
Lotus cohort. Device success was 84% and 64% in
the Lotus and CoreValve arms, respectively, drivenby higher rates of correct positioning of a single
device and lower rates of moderate PAR in the
Lotus group. Importantly, the rates of procedural
mortality and transprosthesis gradient greater than
20 mm Hg and prosthesis patient mismatch were
not different.
It could be argued that the difference we observed
was due to a lower than expected VARC2 device
success rate in the CoreValve group; however,
the rate was comparable to that observed in the
CoreValve arm of the CHOICE trial (Comparison
of balloon-expandable vs. self-expandable valves
in patients undergoing transcatheter aortic valve
replacement) —77.5% (31)—if the same VARC deﬁni-
tion is used. The CHOICE trial used the ﬁrst VARC
FIGURE 2 Secondary Outcome Measures
Comparison of Valve Academic Research Consortium 2 deﬁned outcome measures between the valve types. MI ¼ myocardial infarction; PPM ¼
permanent pacemaker.
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does not include prosthesis-patient mismatch in
the composite endpoint. If the prosthesis-patient
mismatch is not included in the composite, the rates ofTABLE 5 Core Laboratory–Adjudicated Echocardiographic Assessmen
Discharge
Lotus*
(n ¼ 50)
CoreValve†
(n ¼ 48)
Paraprosthetic aortic regurgitation
None/trivial 41 (82) 13 (27.1)
Mild 7 (14) 27 (56.2)
Moderate 2 (4) 8 (16.7)
Moderate/severe 0 0
Severe 0 0
Valvular aortic regurgitation
None/trivial 46 (92) 44 (91.7)
Mild 3 (6) 4 (8.3)
Moderate 1 (2) 0
Moderate/severe 0 0
Severe 0 0
Mean transprosthetic gradient 12.4  4.2 8.5  2.9
Effective oriﬁce area 1.6  0.3 1.7  0.4
Pulmonary artery pressure 41.4  10.8 34.8  8.9
Left ventricular ejection fraction 55.3  10.1 54.5  8.7
Mitral regurgitation
None/trivial 25 (50) 16 (33.3)
Mild 22 (44) 29 (60.4)
Moderate 3 (6) 3 (6.3)
Moderate/severe 0 0
Severe 0 0
Values are n (%) or mean  SD. *Boston Scientiﬁc, Natick, Massachusetts. †Medtronic,device success in our study are 92% and 74% in the
Lotus and CoreValve cohorts, respectively. Moreover,
the rate of moderate PAR observed in this study
was comparable, if not lower, than that observed int
1 Month
p Value
Lotus
(n ¼ 49)
CoreValve
(n ¼ 47) p Value
<0.001 42 (85.7) 11 (23.4) <0.001
7 (14.3) 31 (66)
<0.001 0 5 (10.6) <0.001
0 0
0.04 0 0 0.02
0.95 44 (89.8) 45 (95.7) 0.26
0.65 5 (10.2) 2 (4.3) 0.26
0.33 0 0
0 0
0 0
<0.001 12.6  6.5 8.2  2.6 <0.001
0.07 1.7  0.4 1.8  0.4 0.17
0.03 40.4  10.1 37.0  8.8 0.11
0.70 56.0  8.9 55.3  6.0 0.68
27 (55.1) 20 (42.6)
18 (36.7) 22 (46.8)
4 (8.2) 5 (10.6)
0 0
0.24 0 0 0.68
Minneapolis, Minnesota.
FIGURE 3 Change in New York Heart Association Functional Class
New York Heart Association (NYHA) functional class change at discharge and at 1 month.
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969other core laboratory–adjudicated trials (10,16). The
rate of post-dilation in the CoreValve cohort (26%)
was also comparable to the rate reported in the
CoreValve United States Investigational Device Ex-
emption trial (20.3%) (10). Importantly, the apparent
difference in device success in the current study was
not reﬂected in differences in mortality nor clinical
efﬁcacy to 30 days.
Signiﬁcant PAR after TAVR deployment has been
shown to correlate with increased morbidity and
mortality (32,33). Factors contributing to regurgita-
tion include baseline annular eccentricity (34), the
depth of device implantation (35), and the degree of
prosthesis oversizing (36), whereas the degree of
calciﬁcation has been an inconsistent predictor in
various studies (37–39). In this study, the native basal
plane was slightly more eccentric in the CoreValve
cohort, although whether this contributed to the
device success differences is unclear. The degree
of prosthesis oversizing was greater in the Core-
Valve cohort, although this reﬂected differences in
the manufacturer sizing recommendations for the 2
devices.
The novel features of the Lotus valve may
potentially explain the differences observed in de-
vice success. The Lotus is totally repositionable,
even when fully expanded in the ﬁnal position by
virtue of its deployment and coupling mechanism.
This enables detailed interrogation of the device
function, degree of PAR, and device stability before
uncoupling and release. In addition, the presence of
an adaptive seal around the outer aspect of the
lower valve frame appears to reduce PAR by occu-
pying residual interstices between the frame and
native annulus (17–19). Placement of the CoreValve,
on the other hand, relies on accurate initial posi-
tioning and oversizing of the device to increase
device/annular interaction.
A nonsigniﬁcant reduction in the degree of PAR
was noted between the discharge and 30-day time
points. In the CoreValve cohort, 3 patients with
moderate PAR at discharge had only mild PAR at
30 days. Similarly, 2 patients in the Lotus cohort
had a reduction from moderate to mild PAR.
Detailed interpretation of the mechanism of this
improvement is difﬁcult given the small numbers
but may represent further device expansion, occu-
pation of residual interstices by ﬁbrous tissue, or
sampling error due to different echocardiographic
windows.
Secondary procedural outcome measures including
vascular injury, stroke, myocardial infarction, and
mortality (all-cause and cardiovascular) were not
different between the cohorts and consistent withpreviously reported rates (10,19). There was a numer-
ically but not statistically higher rate of permanent
pacemaker insertion after Lotus device placement.
This study was not powered to identify the cause of
increased pacing; however, in the REPRISE II trials,
pacemaker insertion was found to correlate with the
degree of prosthesis oversizing (40), whichwas greater
than anticipated because only 2 valve sizes were
available.
Core laboratory assessment of the echocardio-
graphic studies at discharge and 30 days showed that
the prosthesis EOA was similar in both cohorts but
that the mean transprosthesis gradient was greater in
the Lotus cohort. Despite well-matched baseline
annular dimensions, a signiﬁcantly larger number of
small prostheses were inserted in the Lotus cohort
due to manufacturer sizing recommendations of less
oversizing with this device. It is possible that the
smaller average device size contributed to a higher
mean gradient.
The results of this well-matched study suggest that
placement of either the CoreValve device or Lotus
device, in appropriately selected high surgical risk
patients, results in acceptable procedural outcomes
with good safety and efﬁcacy proﬁles. The higher rate
of VARC2-deﬁned device success observed in the
Lotus cohort, driven by higher rates of correct posi-
tioning and less PAR, supports the efﬁcacy of the
device’s novel design features.
STUDY LIMITATIONS. This was a small, single-center,
nonrandomized study not powered for major clinical
endpoints such as death, stroke, and MI. Although
every attempt was made to match patients, it is
possible that unrecognized differences between
the study cohorts may have contributed to the
PERSPECTIVES
WHAT IS KNOWN? TAVR is an accepted treatment
modality for appropriately selected patients with
symptomatic severe aortic stenosis, yet modest
complication rates remain.
WHAT IS NEW? New-generation TAVR devices, with
new design features, are entering clinical practice with
potential safety and efﬁcacy advantages over current
devices. We have shown that the mechanically
expanded Lotus device results in higher rates of
device success than the self-expanding CoreValve
device in a matched cohort.
WHAT IS NEXT?The clinical signiﬁcance of
these differences will need to be tested in a larger
randomized trial such as the currently recruiting
REPRISE III study.
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970results. The results should be viewed as hypothesis
generating.
CONCLUSIONS
In this well-matched, single-center, nonrandomized
study, both the CoreValve and Lotus devices de-
monstrated comparable procedural safety and efﬁ-
cacy results. Independent core laboratory assessment
of all echocardiograms suggested greater device suc-
cess with the second-generation Lotus valve driven
by higher rates of correct anatomic positioning of a
single prosthesis and lower rates of moderate para-
prosthetic regurgitation. The clinical signiﬁcance of
these differences will need to be tested in larger
randomized trials such as the REPRISE III trial.
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